“Tradipitant is a selective inhibitor of human cell membrane NK-1 receptor binding,” outlined Dr Vasilios Polymeropoulos (Vanda Pharmaceuticals, NY, USA) [1]. This agent was assessed in participants with a history of motion sickness (n=316). The enrolled participants were randomised 1:1:1 to 170 mg tradipitant, 85 mg tradipitant, or a placebo. The primary outcome was the prevention of vomiting from motion sickness during vehicle travel, as measured by Vomiting Assessment (VA).
The vomiting incidence was 10.4% in the 170 mg arm, significantly lower than the vomiting incidence in the placebo arm (37.7%; P<0.0001). Similarly, the 85 mg arm was associated with a lower vomiting incidence than the placebo arm (18.3% vs 37.7%; P=0.0014). Furthermore, tradipitant intake resulted in a reduced incidence of severe nausea and vomiting (combined tradipitant arms 13.3% vs 33.0%; P<0.0001).
“Overall, tradipitant was effective in reducing vomiting and preventing nausea in this population, with the higher dose displaying slightly better results than the lower dose,” summarised Dr Polymeropoulos. “Given the prevalence of adverse events associated with other therapies such as dimenhydrinate and scopolamine, the well-tolerated agent tradipitant may be beneficial for many travellers.”
- Polymeropoulos V, et al. Motion serifos: tradipitant effective in the prevention of vomiting in motion sickness during sea travel. LB13, UEG Week 2024, 12–15 October, Vienna, Austria.
Medical writing support was provided by Robert van den Heuvel.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« How useful is colonoscopy for constipation in young women? Next Article
Cendakimab meets primary endpoints in eosinophilic oesophagitis »
« How useful is colonoscopy for constipation in young women? Next Article
Cendakimab meets primary endpoints in eosinophilic oesophagitis »
Table of Contents: UEGW 2024
Featured articles
Tamuzimod delivers promising long-term data in ulcerative colitis
CULTIVATE: Good signal for etrasimod in Crohn’s disease
Online First
Upadacitinib associated with normalisation of HRQoL in UC
Diagnostic accuracy of fluorescence confocal laser microscopy after EUS-TA
New insights into perianal fistulising CD pathogenesis may lead to new therapeutics
TL1A inhibitor tulisokibart shows potential in ulcerative colitis
An accelerated treatment approach may save lives in pancreatic walled-off necrosis
Encouraging results for L-carnitine in non-alcoholic fatty liver disease
LOVE-CD: Vedolizumab yields better outcomes in early than in late CD
Tamuzimod delivers promising long-term data in ulcerative colitis
Cendakimab meets primary endpoints in eosinophilic oesophagitis
How useful is colonoscopy for constipation in young women?
Guar gum alleviates IBS-related constipation in randomised-controlled trial
CULTIVATE: Good signal for etrasimod in Crohn’s disease
Meaningful corticosteroid-sparing effect of mirikizumab in UC
Is FMT a viable option to treat primary C. difficile infections?
Extending ustekinumab dosing interval does not influence drug survival in IBD
TACITO: Does FMT improve ICI plus VEGFR TKI therapy in mRCC?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com